When oncology practices, ranging from small community clinics to larger hospital-based programs, were required to adapt their systems virtually overnight in response to the COVID-19 health crisis, almost no one anticipated that these would be long-term changes. However, as September approaches with no end in sight, it has become clear that oncologists will need to adapt revenue cycle management to long-term pandemic-related changes.

As many full-service hospitals and health systems remain overwhelmed due to the COVID-19 pandemic, community cancer providers have been able to offer certain services to patients that may not be available at other institutions. How have these providers adapted to meet patients’ changing needs, and how are they keeping their doors open under unprecedented pressure?

From shuttered laboratory experiments and interrupted clinical trial enrollments to a “shadow curve” of delayed cancer diagnoses, comprehensive cancer centers and integrated delivery networks (IDNs) across the country continue to grapple with the fallout from COVID-19.

One of the most significant questions for payers in the COVID-19 health ecosystem is, “Will reimbursement parity for telehealth services continue?” Leading representatives of major managed care organizations debate the prospects.

As the COVID-19 pandemic stretches into its fifth month in the United States, advocacy groups providing support for patients with cancer are delivering essential support and services, while they worry about the long-term psychosocial impact on these patients and the future of clinical trials.

Shortages, inventory management, and challenges of in-home care were just a few of the topics in AVBCC’s wide-ranging webinar on how COVID-19 is affecting oncology pharmacy.

The COVID-19 pandemic has led to the elimination of several restrictions on telehealth and infusion therapy in the home setting. In this webcast, a panel of experts discuss the short- and long-term prospects for in-home infusion for patients with cancer. What are the benefits and drawbacks?

As we learn more about the complicated behavior of the COVID-19 virus, we have come to understand that overactivation of the patient’s own immune system can often be the most dangerous factor. In this webcast, top cancer experts discuss the latest studies investigating using anti-cancer therapies as treatments for COVID-19. What are some of the options and where does the research stand today?

In this webcast, 3 experts from the independent actuarial firm, Milliman, discussed data on the impact of the COVID-19 pandemic on insurance utilization and costs. The panel explored several factors that may lead to healthcare reform in the months ahead, including the way in which patients and providers approach deferred or avoidable care.

The COVID-19 pandemic will have far-reaching economic implications in the United States and abroad for the foreseeable future. During this session, Murray Aitken, MBA, Director, IQVIA Institute, presented emerging data regarding some of the ways in which the pandemic is affecting the US economy.